Orange Book product · Generic (ANDA)
RIFAMPIN
RIFAMPIN
At a glance
Aug 21, 2013
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 21, 2013
13 yr ago
Today
Pharmaceutical detail
Active ingredient
RIFAMPIN
Strength
150MG
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
ANDA 090034
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of RIFAMPIN
- 1989RIFADINBrand (NDA)
NDA 050627 · SANOFI AVENTIS US
- —RIFADINBrand (NDA)
NDA 050420 · SANOFI AVENTIS US
- —RIMACTANEBrand (NDA)
NDA 050429 · OXFORD PHARMS
- 2016RIFAMPINGeneric (ANDA)
ANDA 205039 · HIKMA PHARMS
- 2016RIFAMPINGeneric (ANDA)
ANDA 206736 · WATSON PHARMS TEVA
- 2014RIFAMPINGeneric (ANDA)
ANDA 091181 · FRESENIUS KABI USA
- 2014RIFAMPINGeneric (ANDA)
ANDA 204101 · AVET LIFESCIENCES
- 2010RIFAMPINGeneric (ANDA)
ANDA 065502 · EPIC PHARMA LLC
- 2008RIFAMPINGeneric (ANDA)
ANDA 065421 · MYLAN LABS LTD
- 2008RIFAMPINGeneric (ANDA)
ANDA 065390 · CHARTWELL MOLECULAR
- 2001RIFAMPINGeneric (ANDA)
ANDA 065028 · HIKMA
- 1999RIFAMPINGeneric (ANDA)
ANDA 064217 · HIKMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
